Early research (Phase 1)Not Yet RecruitingNCT07779798
What this trial is testing
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate Safety, Tolerability, and Clinical Activity of CBX-663 in Participants With Relapsed or Refractory Myeloid Malignancies, Advanced Solid Tumors, or Recurrent or Progressive Glioblastoma.
Who this might be right for
Advanced Solid TumorsRecurrent or Progressive GlioblastomaRelapse or Refractory Myeloid Malignancies
Crossbow Therapeutics, Inc. 120